Skeletal myoblasts for heart regeneration and repair: State of the art and perspectives on the mechanisms for functional cardiac benefits

Current Pharmaceutical Design

Volumn 16, Issue 8, 2010, Pages 915-925

  Formigli, L ^a   Zecchi Orlandini, S ^a   Meacci, E ^a   Bani, D ^a  

^a UNIVERSITY OF FLORENCE   (Italy)

Author keywords

Cardiac regeneration; Paracrine factors; Relaxin; Skeletal myoblast; Sphingosine 1 phosphate

Indexed keywords

GENETIC ENGINEERING; HEART FUNCTION; HEART MUSCLE CONTRACTILITY; HEART MUSCLE INJURY; HEART MUSCLE ISCHEMIA; HUMAN; MUSCLE REGENERATION; MYOBLAST; NONHUMAN; PARACRINE SIGNALING; PRIORITY JOURNAL; REVIEW;

ANIMALS; GENE THERAPY; HEART; HUMANS; MODELS, BIOLOGICAL; MYOBLASTS, SKELETAL; MYOCARDIAL INFARCTION; PARACRINE COMMUNICATION; REGENERATION; STEM CELL TRANSPLANTATION;

EID: 77950236886     PISSN: 13816128     EISSN: None     Source Type: Journal    
DOI: 10.2174/138161210790883390     Document Type: Review

References (231)

1. Rosamond W, Legal K, Friday G, Furies K, Go A, Greenlund K, et al. Heart disease and stroke statistics - 2007 update: a report from the American Heart Association Statistics Committee and Stroke Statistics Subcommittee. Circulation 2007; 115: e69-171.
2. Diwan A, Dorn GW, 2nd. Decompensation of cardiac hypertrophy: cellular mechanisms and novel therapeutic targets. Physiology 2007; 22: 56-64.
3. Swedberg K, Cleland J, Dargie H, Drexler H, Follath F, Komajda M, et al. Guidelines for the diagnosis and treatment of chronic heart failure: executive summary (update 2005): the task force for the diagnosis and treatment of chronic heart failure of the European Society of Cardiology. Eur Heart J 2005; 26: 1115-1140
4. Taylor DA, Atkins BZ, Hungspreugs P, Jones TR, Reedy MC, Hutcheson KA, et al. Regenerating functional myocardium: improved performance after skeletal myoblast transplantation. Nat Med 1998; 4: 929-933
5. Orlic D, Kajstura J, Chimenti S, Jakoniuk I, Anderson SM, Li B, et al. Bone marrow cells regenerate infarcted myocardium. Nature 2001; 410: 701-705
6. Anversa P, Leri A, Kajstura J, Nadal-Ginard B. Myocyte growth and cardiac repair. J Mol Cell Cardiol 2002; 34: 91-105.
7. Cleland JG, Coletta AP, Abdellah AT, Nasir M, Hobson N, Freemantle N, et al. Clinical trials update from the American Heart Association 2006: OAT, SALT 1 and 2, MAGIC, ABCD, PABACHF, IMPROVE-CHF, and percutaneous mitral annuloplasty. Eur J Heart Fail 2007; 9: 92-97
8. Meyer GP, Wollert KC, Lotz J, Steffens J, Lippolt P, Fichtner S, et al. Intracoronary bone marrow cell transfer after myocardial infarction: eighteen months' follow-up data from the randomized, controlled BOOST (BOne marrOw transfer to enhance STelevation infarct regeneration) trial. Circulation 2006; 113: 1287-1294
9. Leri A, Kajstura J, Anversa P, Frishman WH. Myocardial regeneration and stem cell repair. Curr Probl Cardiol 2008; 33: 91-153.
10. Warejcka DJ, Harvey R, Taylor BJ, Young HE, Lucas PA. A population of cells isolated from rat heart capable of differentiating into several mesodermal phenotypes. J Surg Res 1996; 62: 233-242
11. Hierlihy AM, Seale P, Lobe CG, Rudnicki MA, Megeney LA. The post-natal heart contains a myocardial stem cell population. FEBS Lett 2002; 530: 239-243
12. Beltrami AP, Barlucchi L, Torella D, Baker M, Limana F, Chimenti S, et al. Adult cardiac stem cells are multipotent and support myocardial regeneration. Cell 2003; 114: 763-776
13. Oh H, Bradfute SB, Gallardo TD, Nakamura T, Gaussin V, Mishina Y, et al. Cardiac progenitor cells from adult myocardium: homing,differentiation, and fusion after infarction. Proc Natl Acad Sci USA 2003; 100: 12313-12318
14. Oyama T, Nagai T, Wada H, Naito AT, Matsuura K, Iwanaga K, et al. Cardiac side population cells have a potential to migrate and differentiate into cardiomyocytes in vitro and in vivo. J Cell Biol 2007; 176: 329-341
15. Anversa P, Kajstura J, Leri A, Bolli R. Life and death of cardiac stem cells: a paradigm shift in cardiac biology. Circulation 2006; 113: 1451-1463
16. Anversa P, Leri A, Rota M, Hosoda T, Bearzi C, Urbanek K, et al. Concise review: stem cells, myocardial regeneration, and methodological artifacts. Stem Cells 2007; 25: 589-601.
17. Lyngbaek S, Schneider M, Hansen JL, Sheikh SP. Cardiac regeneration by resident stem and progenitor cells in the adult heart. Basic Res Cardiol 2007; 102: 101-114
18. Guan K, Hasenfuss G. Do stem cells in the heart truly differentiate into cardiomyocytes? J Mol Cell Cardiol 2007; 43: 377-387
19. Dib N, Dinsmore J, Lababidi Z, White B, Moravec S, Campbell A, et al. One-year follow-up of feasibility and safety of the first US, randomized, controlled study using 3-dimensional guided catheterbased delivery of autologous skeletal myoblasts for ischemic cardiomyopathy (CAuSMIC study). JACC Cardiovasc Interv 2009; 2: 9-16.
20. Kao RL, Ganote CE, Pennington DG, Browder IW. Myocardial regeneration, tissue engineering and therapy. In Prakash S, Ed. Artificial cells, cell engineering and therapy. Cambridge: Woodhead Publishing Ltd. 2007; pp. 349-365.
21. Menasché P. Skeletal myoblasts as a therapeutic agent. Prog Cardiovasc Dis 2007; 50: 7-17.
22. Liao R, Pfister O, Jain M, Mouquet F. The bone marrow - cardiac axis of myocardial regeneration. Prog Cardiovasc Dis 2007; 50: 18-30.
23. Prockop DJ, Olson SD. Clinical trials with adult stem/progenitor cells for tissue repair: let's not overlook some essential precautions. Blood 2007; 109: 3147-3151
24. Segers VF, Lee RT. Stem-cell therapy for cardiac disease. Nature 2008; 451: 937-942
25. Hagege AA, Carrion C, Menasche P, Vilquin JT, Duboc D, Marolleau JP, et al. Viability and differentiation of autologous skeletal myoblast grafts in ischaemic cardiomyopathy. Lancet 2003; 361: 491-492
26. Menasché P, Hagège AA, Vilquin JT, Desnos M, Abergel E, Pouzet B, et al. Autologous skeletal myoblast transplantation for severe postinfarction left ventricular dysfunction. J Am Coll Cardiol 2003; 41: 1078-1083
27. Formigli L, Perna AM, Meacci E, Cinci L, Margheri M, Nistri S, et al. Paracrine effects of transplanted myoblasts and relaxin on postinfarction heart remodelling. J Cell Mol Med 2007; 11: 1087-1100
28. Ghostine S, Carrion C, Souza LC, Richard P, Bruneval P, Vilquin JT, et al. Long-term efficacy of myoblast transplantation on regional structure and function after myocardial infarction. Circulation 2002; 106: I131-6.
29. van den Bos EJ, Thompson RB, Wagner A, Mahrholdt H, Morimoto Y, Thomson LE, et al. Functional assessment of myoblast transplantation for cardiac repair with magnetic resonance imaging. Eur J Heart Fail 2005; 7: 435-443
30. Haider HK, Lei Y, Ashraf M. MyoCell, a cell-based, autologous skeletal myoblast therapy for the treatment of cardiovascular diseases. Curr Opin Mol Ther 2008; 10: 611-621
31. Menasché P, Alfieri O, Janssens S, McKenna W, Reichenspurner H, Trinquart L, et al. The Myoblast Autologous Grafting in Ischemic Cardiomyopathy (MAGIC) trial: first randomized placebo-controlled study of myoblast transplantation. Circulation 2008; 117: 1189-1200
32. Murry CE, Wiseman RW, Schwartz SM, Hauschka SD. Skeletal myoblast transplantation for repair of myocardial necrosis. J Clin Invest 1996; 98: 2512-2523
33. Al Attar N, Carrion C, Ghostine S, Garcin I, Vilquin JT, Hagège AA, et al. Long-term (1 year) functional and histological results of autologous skeletal muscle cells transplantation in rat. Cardiovasc Res 2003; 58: 142-148
34. Tezuka A, Kawada T, Nakazawa M, Masui F, Konno S, Nitta S, et al. Which skeletal myoblasts and how to be transplanted for cardiac repair? Biochem Biophys Res Commun 2008; 369: 270-276
35. Reinecke H, Poppa V, Murry CE. Skeletal muscle stem cells do not transdifferentiate into cardiomyocytes after cardiac grafting. J Mol Cell Cardiol 2002; 34: 241-249
36. Leobon B, Garcin I, Menasche P, Vilquin JT, Audinat E, Charpak S. Myoblasts transplanted into rat infarcted myocardium are functionally isolated from their host. Proc Natl Acad Sci USA 2003; 100: 7808-7811
37. Balogh S, Naus CC, Merrifield PA. Expression of gap junctions in cultured rat L6 cells during myogenesis. Dev Biol 1993; 155: 351-360
38. Reinecke H, MacDonald GH, Hauschka SD, Murry CE. Electromechanical coupling between skeletal and cardiac muscle. Implications for infarct repair. J Cell Biol 2000; 149: 731-740
39. Formigli L, Francini F, Tani A, Squecco R, Nosi D, Polidori L, et al. Morphofunctional integration between skeletal myoblasts and adult cardiomyocytes in coculture is favored by direct cell-cell contacts and relaxin treatment. Am J Physiol Cell Physiol 2005; 288: C795-804.
40. Squecco R, Sassoli C, Nuti F, Martinesi M, Chellini F, Nosi D, et al. Sphingosine 1-phosphate induces myoblast differentiation through Cx43 protein expression: a role for a gap junctiondependent and -independent function. Mol Biol Cell 2006; 17: 4896-4910
41. Hagège AA, Marolleau JP, Vilquin JT, Alh́ritìre A, Peyrard S, Duboc D, et al. Skeletal myoblast transplantation in ischemic heart failure: long-term follow-up of the first phase I cohort of patients. Circulation 2006; 114: I108-13.
42. Fernandes S, Amirault JC, Lande G, Nguyen JM, Forest V, Bignolais O, et al. Autologous myoblast transplantation after myocardial infarction increases the inducibility of ventricular arrhythmias. Cardiovasc Res 2006; 69: 299-301.
43. Ye L, Haider HK, Sim EK. Adult stem cells for cardiac repair: a choice between skeletal myoblasts and bone marrow stem cells. Exp Biol Med (Maywood) 2006; 231: 8-19.
44. Urish KL, Vella JB, Okada M, Deasy BM, Tobita K, Keller BB, et al. Antioxidant levels represent a major determinant in the regenerative capacity of muscle stem cells. Mol Biol Cell 2009; 20: 509-520
45. van den Bos EJ, van der Giessen WJ, Duncker DJ. Cell transplantation for cardiac regeneration: where do we stand? Neth Heart J 2008; 16: 88-95.
46. Schuldt AJ, Rosen MR, Gaudette GR, Cohen IS. Repairing damaged myocardium: evaluating cells used for cardiac regeneration. Curr Treat Options Cardiovasc Med 2008; 10: 59-72.
47. Joggerst SJ, Hatzopoulos AK. Stem cell therapy for cardiac repair: benefits and barriers. Expert Rev Mol Med 2009; 11: e20.
48. Zhuang J, Yamada KA, Saffitz JE, Kléber AG. Pulsatile stretch remodels cell-to-cell communication in cultured myocytes. Circ Res 2000; 87: 316-322
49. Shanker AJ, Yamada K, Green KG, Yamada KA, Saffitz JE. Matrix-protein-specific regulation of Cx43 expression in cardiac myocytes subjected to mechanical load. Circ Res 2005; 96: 558-566
50. Formigli L, Meacci E, Sassoli C, Chellini F, Giannini R, Quercioli F, et al. Sphingosine 1-phosphate induces cytoskeletal reorganization in C2C12 myoblasts: physiological relevance for stress fibres in the modulation of ion current through stretch-activated channels. J Cell Sci 2005; 118: 1161-1171
51. Formigli L, Meacci E, Sassoli C, Squecco R, Nosi D, Chellini F, et al. Cytoskeleton/stretch-activated ion channel interaction regulates myogenic differentiation of skeletal myoblasts. J Cell Physiol 2007; 211: 296-306.
52. Sbrana F, Sassoli C, Meacci E, Nosi D, Squecco R, Paternostro F, et al. Role for stress fiber contraction in surface tension development and stretch-activated channel regulation in C2C12 myoblasts. Am J Physiol Cell Physiol 2008; 295: C160-72.
53. Formigli L, Sassoli C, Squecco R, Bini F, Martinesi M, Chellini F, et al. Regulation of transient receptor potential canonical channel 1 (TRPC1) by sphingosine 1-phosphate in C2C12 myoblasts and its relevance for a role of mechanotransduction in skeletal muscle differentiation. J Cell Sci 2009; 122: 1322-1333
54. Zebedin E, Mille M, Speiser M, Zarrabi T, Sandtner W, Latzenhofer B, et al. C2C12 skeletal muscle cells adopt cardiac-like sodium current properties in a cardiac cell environment. Am J Physiol Heart Circ Physiol 2007; 292: H439-50.
55. Roell W, Lewalter T, Sasse P, Tallini YN, Choi BR, Breitbach M, et al. Engraftment of connexin 43-expressing cells prevents postinfarct arrhythmia. Nature 2007; 450: 819-824
56. Abraham MR, Henrikson CA, Tung L, Chang MG, Aon M, Xue T, et al. Antiarrhythmic engineering of skeletal myoblasts for cardiac transplantation. Circ Res 2005; 97: 159-167
57. Suzuki K, Murtuza B, Smolenski RT, Sammut IA, Suzuki N, Kaneda Y, et al. Cell transplantation for the treatment of acute myocardial infarction using vascular endothelial growth factorexpressing skeletal myoblasts. Circulation 2001; 104: I207-12.
58. Fernandes S, van Rijen HV, Forest V, Evain S, Leblond AL, Mérot J, et al. Cardiac cell therapy: overexpression of connexin43 in skeletal myoblasts and prevention of ventricular arrhythmias. J Cell Mol Med 2009; Mar 6 [Epub ahead of print].
59. Niagara MI, Haider HK, Jiang S, Ashraf M. Pharmacologically preconditioned skeletal myoblasts are resistant to oxidative stress and promote angiomyogenesis via release of paracrine factors in the infarcted heart. Circ Res 2007; 100:545-555
60. Suzuki K, Smolenski RT, Jayakumar J, Murtuza B, Brand NJ, Yacoub MH. Heat shock treatment enhances graft cell survival in skeletal myoblas transplantation to the heart. Circulation 2000; 102: III-216-221
61. Germani A, Di Carlo A, Mangoni A, Straino S, Giacinti C, Turrini P, et al. Vascular endothelial growth factor modulates skeletal myoblast function. Am J Pathol 2003; 163: 1417-1428
62. Law PK, Haider K, Fang G, Jiang S, Chua F, Lim YT, et al. Human VEGF165-myoblasts produce concomitant angiogenesis/myogenesis in the regenerative heart. Mol Cell Biochem 2004; 263: 173-178
63. Murtuza B, Suzuki K, Bou-Gharios G, Beauchamp JR, Smolenski RT, Partridge TA, et al. Transplantation of skeletal myoblasts secreting an IL-1 inhibitor modulates adverse remodeling in infarcted murine myocardium. Proc Natl Acad Sci USA 2004; 101: 4216-4221
64. Bonaros N, Rauf R, Werner E, Schlechta B, Rohde E, Kocher A, et al. Neoangiogenesis after combined transplantation of skeletal myoblasts and angiopoietic progenitors leads to increased cell engraftment and lower apoptosis rates in ischemic heart failure. Interact Cardiovasc Thorac Surg 2008; 7: 249-255
65. Hamdi H, Furuta A, Bellamy V, Bel A, Puymirat E, Peyrard S, et al. Cell delivery: intramyocardial injections or epicardial deposition? A head-to-head comparison. Ann Thorac Surg 2009; 87: 1196-1204
66. Pacak CA, Cowan DB. Fabrication of myogenic engineered tissue constructs. J Vis Exp 2009; (27)pii: 1137. doi: 10.3791/1137.
67. Sherwood RI, Christensen JL, Conboy IM, Conboy MJ, Rando TA, Weissman IL, et al. Isolation of adult mouse myogenic progenitors: functional heterogeneity of cells within and engrafting skeletal muscle. Cell 2004; 119: 543-554
68. Zammit PS, Golding JP, Nagata Y, Hudon V, Partridge TA, Beauchamp JR. Muscle satellite cells adopt divergent fates: a mechanism for self-renewal? J Cell Biol 2004; 166: 347-357
69. Kuang S, Kuroda K, Le Grand F, Rudnicki MA. Asymmetric selfrenewal and commitment of satellite stem cells in muscle. Cell 2007; 129: 999-1010.
70. Kuang S, Gillespie MA, Rudnicki MA. Niche regulation of muscle satellite cell self-renewal and differentiation. Cell Stem Cell 2008; 2: 22-31.71.
71. Collins CA, Olsen I, Zammit PS, Heslop L, Petrie A, Partridge TA, et al. Stem cell function, self-renewal, and behavioral heterogeneity of cells from the adult muscle satellite cell niche. Cell 2005; 122: 289-301.
72. Shi X, Garry DJ. Muscle stem cells in development, regeneration, and disease. Genes Dev 2006; 20: 1692-1708
73. Arsic N, Mamaeva D, Lamb NJ, Fernandez. Muscle-derived stem cells isolated as non-adherent population give rise to cardiac, skeletal muscle and neural lineages. Exp Cell Res 2008; 314: 1266-1280
74. Cooper RN, Butler-Browne GS, Mouly V. Human muscle stem cells. Curr Opin Pharmacol 2006; 6: 295-300.
75. Oshima H, Payne TR, Urish KL, Sakai T, Ling Y, Gharaibeh B, et al. Differential myocardial infarct repair with muscle stem cells compared to myoblasts. Mol Ther 2005; 12: 1130-1141
76. Payne TR, Oshima H, Sakai T, Ling Y, Gharaibeh B, Cummins J, et al. Regeneration of dystrophin-expressing myocytes in the mdx heart by skeletal muscle stem cells. Gene Ther 2005; 12: 1264-1274
77. Tousoulis D, Briasoulis A, Antoniades C, Stefanadi E, Stefanadis C. Heart regeneration: what cells to use and how? Curr Opin Pharmacol 2008; 8: 211-218
78. Gnecchi M, Zhang Z, Ni A, Dzau VJ. Paracrine mechanisms in adult stem cell signaling and therapy. Circ Res 2008; 103: 1204-1219
79. Aupperle H, Garbade J, Schubert A, Barten M, Dhein S, Schoon HA, et al. Effects of autologous stem cells on immunohistochemical patterns and gene expression of metalloproteinases and their tissue inhibitors in doxorubicin cardiomyopathy in a rabbit model. Vet Pathol 2007; 44: 494-503.
80. Burchfield JS, Dimmeler S. Role of paracrine factors in stem and progenitor cell mediated cardiac repair and tissue fibrosis. Fibrogenesis Tissue Repair 2008; 1: 1-11.
81. Leri A, Kajstura J, Anversa P. Cardiac stem cells and mechanisms of myocardial regeneration Physiol Rev 2005; 85: 1373-1416
82. Payne TR, Oshima H, Okada M, Momoi N, Tobita K, Keller BB, et al. A relationship between vascular endothelial growth factor, angiogenesis, and cardiac repair after muscle stem cell transplantation into ischemic hearts. J Am Coll Cardiol 2007; 50: 1677-1684
83. Jiang M, Wang B, Wang C, He B, Fan H, Guo TB, et al. Angiogenesis by transplantation of HIF-1 α modified EPCs into ischemic limbs. J Cell Biochem 2008; 103: 321-334
84. Gnecchi M, He H, Noiseux N, Liang OD, Zhang L, Morello F, et al. Evidence supporting paracrine hypothesis for Akt-modified mesenchymal stem cell-mediated cardiac protection and functional improvement. FASEB J 2006; 20: 661-669
85. Doyle B, Sorajja P, Hynes B, Kumar AH, Araoz PA, Stalboerger PG, et al. Progenitor cell therapy in a porcine acute myocardial infarction model induces cardiac hypertrophy, mediated by paracrine secretion of cardiotrophic factors including TGF-β1. Stem Cells Dev 2008; 17: 941-951
86. Xu M, Uemura R, Dai Y, Wang Y, Pasha Z, Ashraf M. In vitro and in vivo effects of bone marrow stem cells on cardiac structure and function. J Mol Cell Cardiol 2007; 42: 441-448
87. Maulik N, Thirunavukkarasu M. Growth factors and cell therapy in myocardial regeneration. J Mol Cell Cardiol 2008; 44: 219-227
88. Dimmeler S, Burchfield J, Zeiher AM. Cell-Based Therapy of Myocardial Infarction. Arterioscler Thromb Vasc Biol 2008; 28: 208-216
89. Perez-Ilzarbe M, Agbulut O, Pelacho B, Ciorba C, San Jose-Eneriz E, Desnos M, et al. Characterization of the paracrine effects of human skeletal myoblasts transplanted in infarcted myocardium. Eur J Heart Fail 2008; 10: 1065-1072
90. Lee J, Stagg MA, Siedlecka U, Latif N, Soppa GK, Yacoub M, et al. Identification of cell-specific soluble mediators and cellular targets during cell therapy for the treatment of heart failure. Regen Med 2008; 3: 953-962
91. Spinale FG. Matrix metalloproteinases: regulation and dysregulation in the failing heart. Circ Res 2002; 90: 520-530
92. Bonacchi M, Nistri S, Nanni C, Gelsomino S, Pini A, Cinci L, et al. Functional and histopathological improvement of the post-infarcted rat heart upon myoblast cell grafting and relaxin therapy. J Cell Mol Med 2008; Sep. 15 [Epub ahead of print].
93. Gavira JJ, Perez-Ilzarbe M, Abizanda G, García-Rodríguez A, Orbe J, Páramo JA, et al. A comparison between percutaneous and surgical transplantation of autologous skeletal myoblasts in a swine model of chronic myocardial infarction. Cardiovasc Res 2006; 7: 744-753
94. Hoashi T, Matsumiya G, Miyagawa S, Ichikawa H, Ueno T, Ono M, et al. Skeletal myoblast sheet transplantation improves the diastolic function of a pressure-overloaded right heart. J Thorac Cardiovasc Surg 2009; 138: 460-467
95. Hierlihy AM, Seale P, Lobe CG, Rudnicki MA, Megeney LA. The post-natal heart contains a myocardial stem cell population. FEBS Lett 2002; 530: 239-243
96. Beltrami AP, Barlucchi L, Torella D, Baker M, Limana F, Chimenti S, et al. Adult cardiac stem cells are multipotent and support myocardial regeneration. Cell 2003; 114: 763-776
97. Oh H, Bradfute SB, Gallardo TD, Nakamura T, Gaussin V, Mishina Y, et al. Cardiac progenitor cells from adult myocardium: homing, differentiation, and fusion after infarction. Proc Natl Acad Sci USA 2003; 100: 12313-12318
98. Torella D, Ellison GM, Karakikes I, Nadal-Ginard B. Resident cardiac stem cells. Cell Mol Life Sci 2007; 64: 661-673
99. Ott HC, Taylor DA. From cardiac repair to cardiac regeneration - ready to translate? Expert Opin Biol Ther 2006; 6: 867-878
100. Segers VF, Lee RT. Stem-cell therapy for cardiac disease. Nature 2008; 451: 937-942
101. Torella D, Ellison GM, Karakikes I, Nadal-Ginard B. Growthfactor-mediated cardiac stem cell activation in myocardial regeneration. Nat Clin Pract Cardiovasc Med 2007; 4(Suppl 1): S52-9.
102. Chamuleau SA, Vrijsen KR, Rokosh DG, Tang XL, Piek JJ, Bolli R. Cell therapy for ischaemic heart disease: focus on the role of resident cardiac stem cells. Neth Heart J 2009; 17: 199-207.
103. Yu XY, Geng YJ, Li XH, Lin QX, Shan ZX, Lin SG, et al. The effects of mesenchymal stem cells on c-kit up-regulationand cellcycle re-entry of neonatal cardiomyocytes are mediated by activation of insulin-like growth factor 1 receptor. Mol Cell Biochem 2009; 332(1-2): 25-32.
104. Urbich C, Aicher A, Heeschen C, Dernbach E, Hofmann WK, Zeiher AM, et al. Soluble factors released by endothelial progenitor cells promote migration of endothelial cells and cardiac resident progenitor cells. J Mol Cell Cardiol 2005; 39: 733-742
105. Nakanishi C, Yamagishi M, Yamahara K, Hagino I, Mori H, Sawa Y, et al. Activation of cardiac progenitor cells through paracrine effects of mesenchymal stem cells. Biochem Biophys Res Comm 2008; 374: 11-16
106. Urbanek K, Rota M, Cascapera S, Bearzi C, Nascimbene A, De Angelis A, et al. Cardiac stem cells possess growth factor-receptor systems that after activation regenerate the infarcted myocardium, improving ventricular function and long-term survival. Circ Res 2005; 97: 663-673
107. Atkins BZ, Lewis CW, Kraus WE, Hutcheson KA, Glower DD, Taylor DA. Intracardiac transplantation of skeletal myoblasts yields two populations of striated cells in situ. Ann Thorac Surg 1999; 67: 124-129
108. Formigli L, Francini F, Nistri S, Margheri M, Luciani G, Naro F, et al. Skeletal myoblasts overexpressing relaxin improve differentiation and communication of primary murine cardiomyocyte cell cultures. J Mol Cell Cardiol 2009; 47: 335-345
109. Popescu LM, Gherghiceanu M, Manole CG, Faussone-Pellegrini MS. Cardiac renewing: interstitial Cajal-like cells nurse cardiomyocytes progenitors in epicardial stem cell niche. J Cell Mol Med 2009; 13: 866-886
110. Schabort EJ, Myburgh KH, Wiehe JM, Torzewski J, Niesler CU. Potential myogenic stem cell populations: sources, plasticity, and application for cardiac repair. Stem Cells Dev 2009; 18: 813-830
111. Haider HK, Ye L, Ashraf M. Skeletal muscle derived stem cells for myocardial repair. Recent Pat Cardiovasc Drug Discov 2007; 2: 205-213
112. Shintani Y, Fukushima S, Varela-Carver A, Lee J, Coppen SR, Takahashi K, et al. Donor cell-type specific paracrine effects of cell transplantation for post-infarction heart failure. J Mol Cell Cardiol 2009; 47: 288-295
113. Vandervelde S, van Luyn MJ, Tio RA, Harmsen MC. Signaling factors in stem cell-mediated repair of infarcted myocardium. J Mol Cell Cardiol 2005; 39: 363-376
114. KakinumaY, Miyauchi T, Yuki K, Murakoshi N, Goto K, Yamaguchi I. Novel molecular mechanism of increased myocardial endothelin- 1 expression in the failing heart involving the transcriptional factor hypoxia-inducible factor-1 induced for impaired myocardial energy metabolism. Circulation 2001; 103: 2387-2394
115. Semenza GL. Hypoxia-inducible factor 1: control of oxygen homeostasis in health and disease. Pediatr Res 2001; 49: 614-617
116. Compernolle V, Brusselmans K, Franco D, Moorman A, Dewerchin M, Collen D, et al. Cardia bifida, defective heart development and abnormal neural crest migration in embryos lacking hypoxiainducible factor-1alpha. Cardiovasc Res 2003; 60: 569-579
117. Shohet RV, Garcia JA. Keeping the engine primed: HIF factors as key regulators of cardiac metabolism and angiogenesis during ischemia. J Mol Med 2007; 85: 1309-1315
118. Huang Y, Hickey RP, Yeh JL, Liu D, Dadak A, Young LH, et al. Cardiac myocyte-specific HIF-1 deletion alters vascularization, energy availability, calcium flux, and contractility in the normoxic heart. FASEB J 2004; 18: 1138-1140
119. Shyu K, Wang MT, Wang BW, Chang CC, Leu JG, Kuan P, et al. Intramyocardial injection of naked DNA encoding HIF- 1 / VP16 hybrid to enhance angiogenesis in an acute myocardial infarction model in the rat. Cardiovasc Res 2002; 54: 576-583
120. Leung DW, Cachianes G, Kuang WJ, Goeddel DV, Ferrara N. Vascular endothelial growth factor is a secreted angiogenic mitogen. Science 1989; 246: 1306-1309
121. Ferrara N, Gerber HP, LeCouter J. The biology of VEGF and its receptors. Nat Med 2003: 9: 669-676
122. Robinson CJ, Stringer SE. The splice variants of vascular endothelial growth factor (VEGF) and their receptors. J Cell Sci 2001; 114(Pt 5): 853-865
123. Nieves BJ, D'Amore PA, Bryan BA. The function of vascular endothelial growth factor. Biofactors 2009; 35: 332-337
124. Banai S, Shweiki D, Pinson A, Chandra M, Lazarovici G, Keshet E. Upregulation of vascular endothelial growth factor expression induced by myocardial ischaemia: implications for coronary angiogenesis. Cardiovasc Res 1994; 28:1176-1179
125. Menasché P. Skeletal myoblasts and cardiac repair. J Mol Cell Cardiol 2008; 45: 545-553
126. Laguens R, Cabeza MP, Vera JG, Del Valle H, Lascano E, Negroni J, et al. Entrance in mitosis of adult cardiomyocytes in ischemic pig hearts after plasmid-mediated rhVEGF165 gene transfer. Gene Ther 2002; 9: 1676-1681
127. Law PK, Haider K, Fang G, Jiang S, Chua F, Lim YT, et al. Human VEGF165-myoblasts produce concomitant angiogenesis/myogenesis in the regenerative heart. Mol Cell Biochem 2004; 263: 173-178
128. Ye L, Haider HK, Jiang S, Ling LH, Ge R, Law PK, et al. Reversal of myocardial injury using genetically modulated human skeletal myoblasts in a rodent cryoinjured heart model. Eur J Heart Fail 2005; 7: 945-952
129. Pavoine C, Pecker F. Sphingomyelinases: their regulation and roles in cardiovascular pathophysiology. Cardiovasc Res 2009; 82: 175-183
130. Means CK, Brown JH. Sphingosine-1-phosphate receptor signalling in the heart.Cardiovasc Res 2009; 82: 193-200.
131. Karliner JS, Brown JH. Lipid signalling in cardiovascular pathophysiology. Cardiovasc Res 2009; 82: 171-174
132. Tao R, Zhang J, Vessey DA, Honbo N, Karliner JS. Deletion of the sphingosine kinase-1 gene influences cell fate during hypoxia and glucose deprivation in adult mouse cardiomyocytes. Cardiovasc Res 2007; 74: 56-63.
133. Nishino Y, Webb I, Marber MS. Sphingosine kinase isoforms and cardiac protection. Cardiovasc Res 2007; 76: 3-4.
134. Theilmeier G, Schmidt C, Herrmann J, Keul P, Schafers M, Herrgott I, et al. High-density lipoproteins and their constituent, sphingosine-1-phosphate, directly protect the heart against ischemia/reperfusion injury in vivo via the S1P3 lysophospholipid receptor. Circulation 2006; 114: 1403-1409
135. Landeen LK, Dederko DA, Kondo CS, Hu BS, Aroonsakool N, Haga JH, et al. Mechanisms of the negative inotropic effects of sphingosine-1-phosphate on adult mouse ventricular myocytes. Am J Physiol Heart Circ Physiol 2008; 294: H736-H49.
136. Means CK, Brown JH. Sphingosine-1-phosphate receptor signalling in the heart. Cardiovasc Res 2009; 82: 193-200.
137. Hofmann U, Burkard N, Vogt C, Thoma A, Frantz S, Ertl G, et al. Protective effects of sphingosine-1-phosphate receptor agonist treatment after myocardial ischaemia reperfusion. Cardiovasc Res 2009; 83: 285-293
138. Kennedy S, Kane KA, Pyne NJ, Pyne S. Targeting sphingosine-1-phosphate signalling for cardioprotection. Curr Opin Pharmacol 2009; 9: 194-201.
139. Yeh C, Li H, Malhotra D, Huang M, Zhu B, Goetzl EJ, et al. Sphingolipid signaling and treatment during remodeling of the uninfarcted ventricular wall after myocardial infarction. Am J Physiol Heart Circ Physiol 2009; 296: H1193-H9.
140. Kim RH, Takabe K, Milstien S, Spiegel S. Export and functions of sphingosine-1-phosphate. Biochim Biophys Acta 2009; 1791: 692-696
141. Meacci E, Cencetti F, Donati C, Nuti F, Becciolini L, Bruni P. Sphingosine kinase activity is required for sphingosine-mediated phospholipase D activation in C2C12 myoblasts. Biochem J 2004; 381: 655-663
142. Meacci E, Nuti F, Donati C, Cencetti F, Farnararo M, Bruni P. Sphingosine kinase activity is required for myogenic differentiation of C2C12 myoblasts. J Cell Physiol 2008; 214: 210-220
143. Naldini L, Vigna E, Narsimhan RP, Gaudino G, Zarnegar R, Michalopoulos GK, et al. Hepatocyte growth factor (HGF) stimulates the tyrosine kinase activity of the receptor encoded by the proto-oncogene c-MET. Oncogene 1991; 6: 501-504
144. Chargé SB, Rudnicki MA. Cellular and molecular regulation of muscle regeneration. Physiol Rev 2004; 84: 209-238
145. Rappolee DA, Iyer A, Patel Y. Hepatocyte growth factor and its receptor are expressed in cardiac myocytes during early cardiogenesis. Circ Res 1996; 78: 1028-1036
146. Ueda H, Nakamura T, Matsumoto K, Sawa Y, Matsuda H, Nakamura T. A potential cardioprotective role of hepatocyte growth factor in myocardial infarction in rats. Cardiovasc Res 2001; 51: 41-50.
147. Nakamura T, Mizuno S, Matsumoto K, Sawa Y, Matsuda H, Nakamura T. Myocardial protection from ischemia/reperfusion injury by endogenous and exogenous HGF. J Clin Invest 2000; 106: 1511-1519
148. Yang ZJ, Xu SL, Chen B, Zhang SL, Zhang YL, Wei W, et al. Hepatocyte growth factor plays a critical role in the regulation of cytokine production and induction of endothelial progenitor cell mobilization: a pilot gene therapy study in patients with coronary heart disease. Clin Exp Pharmacol Physiol 2009; 36: 790-796
149. Kondoh H, Sawa Y, Fukushima N, Matsumiya G, Miyagawa S, Kitagawa-Sakakida S, et al. Combined strategy using myoblasts and hepatocyte growth factor in dilated cardiomyopathic hamsters. Ann Thorac Surg 2007; 84: 134-141
150. Stewart CE, Rotwein P. Growth, differentiation, and survival: multiple physiological functions for insulin-like growth factors. Physiol Rev 1996; 76: 1005-1026
151. Foncea R, Andersson M, Ketterman A, Blakesley V, Sapag-Hagar M, Sugden PH, et al. Insulinlike growth factor-I rapidly activates multiple signal transduction pathways in cultured rat cardiac myocytes. J Biol Chem 1997; 272: 19115-19124
152. Saetrum-Opgaard O, Wang PH. IGF-I is a matter of heart. Growth Horm IGF Res 2005; 15: 89-94.
153. Welch S, Plank D, Witt S, Glascock B, Schaefer E, Chimenti S, et al. Cardiac specific IGF-1 expression attenuates dilated cardiomyopathy in tropomodulin-overexpressing transgenic mice. Circ Res 2002; 90: 641-648
154. Duerr RL, Huang S, Miraliakbar HR, Clark R, Chien KR, Ross J, Jr. Insulin-like growth factor-1 enhances ventricular hypertrophy and function during the onset of experimental cardiac failure. J Clin Invest 1995; 95: 619-627
155. Abe N, Matsunaga T, Kameda K, Tomita H, Fujiwara T, Ishizaka H, et al. Increased level of pericardial insulin-like growth factor-1 in patients with left ventricular dysfunction and advanced heart failure. J Am Coll Cardiol 2006; 48:1387-1395
156. Serose A, Salmon A, Fiszman MY, Fromes Y. Short-term treatment using insulin-like growth factor-1 (IGF-1) improves life expectancy of the delta-sarcoglycan deficient hamster. J Gene Med 2006; 8: 1048-1055
157. Kanemitsu N, Tambara K, Premaratne GU, Kimura Y, Tomita S, Kawamura T, et al. Insulin-like growth factor-1 enhances the efficacy of myoblast transplantation with its multiple functions in the chronic MI rat model. J Heart Lung Transplant 2006; 25: 1253-1262
158. Schertzer JD, Lynch GS. Comparative evaluation of IGF-I gene transfer and IGF-I protein administration for enhancing skeletal muscle regeneration after injury. Gene Ther 2006; 13: 1657-1664
159. Philippou A, Maridaki M, Halapas A, Koutsilieris M. The role of the insulin-like growth factor 1 (IGF-1) in skeletal muscle physiology. In Vivo 2007; 21: 45-54.
160. Palmen M, Daemen MJ, De Windt LJ, Willems J, Dassen WR, Heeneman S, et al. Fibroblast growth factor-1 improves cardiac functional recovery and enhances cell survival after ischemia and reperfusion: a fibroblast growth factor receptor, protein kinase C, and tyrosine kinase-dependent mechanism. J Am Coll Cardiol 2004; 44: 1113-1123
161. Kharitonenkov A. FGFs and metabolism. Curr Opin Pharmacol 2009; Aug 14 [Epub ahead of print].
162. Kardami E, Detillieux K, Ma X, Jiang Z, Santiago JJ, Jimenez SK, et al. Fibroblast growth factor-2 and cardioprotection. Heart Fail Rev 2007; 12: 267-277
163. Clarke MSF, Caldwell RW, Chiao H, Miyake K, McNeil PL. Contraction-induced cell wounding and release of fibroblast growth factor in heart. Circ Res 1995; 76: 927-934
164. Htun P, Ito WD, Hoefer IE, Schaper J, Schaper W. Intramyocardial infusion of FGF-1 mimics ischemic preconditioning in pig myocardium, J Mol Cell Cardiol 1998; 30: 867-877
165. Dell'Era P, Ronca R, Coco L, Nicoli S, Metra M, Presta M. Fibroblast growth factor receptor-1 is essential for in vitro cardiomyocyte development. Circ Res 2003; 93: 414-420
166. Kawai T, Takahashi T, Esaki M, Ushikoshi H, Nagano S, Fujiwara H, et al. Efficient cardiomyogenic differentiation of embryonic stem cell by fibroblast growth factor 2 and bone morphogenetic protein 2. Circ J 2004; 68: 691-702.
167. Detillieux KA, Sheikh F, Kardami E, Cattini PA. Biological activities of fibroblast growth factor-2 in the adult myocardium. Cardiovasc Res 2003; 57: 8-19.
168. Liu L, Pasumarthi KB, Padua RR, Massaeli H, Fandrich RR, Pierce GN, et al. Adult cardiomyocytes express functional high-affinity receptors for basic fibroblast growth factor. Am J Physiol 1995; 268: H1927-38.
169. Pillarisetti K, Gupta SK. Cloning and relative expression analysis of rat stromal cell derived factor-1 (SDF-1)1: SDF-1 alpha mRNA is selectively induced in rat model of myocardial infarction. Inflammation 2001; 25: 293-300.
170. Zou YR, Kottmann AH, Kuroda M, Taniuchi I, Littman DR. Function of the chemokine receptor CXCR4 in haematopoiesis and in cerebellar development. Nature 1998; 393: 595-599
171. Askari AT, Unzek S, Popovic ZB, Goldman CK, Forudi F, Kiedrowski M, et al. Effect of stromal-cell-derived factor 1 on stem-cell homing and tissue regeneration in ischaemic cardiomyopathy. Lancet 2003; 362: 697-703.
172. Kucia M, Dawn B, Hunt G, Guo Y, Wysoczynski M, Majka M, et al. Cells expressing early cardiac markers reside in the bone marrow and are mobilized into the peripheral blood after myocardial infarction. Circ Res 2004; 95:1191-1199
173. Moore MA, Hattori K, Heissig B, Shieh JH, Dias S, Crystal RG, et al. Mobilization of endothelial and hematopoietic stem and progenitor cells by adenovector-mediated elevation of serum levels of SDF-1,VEGF, and angiopoietin-1. Ann NY Acad Sci 2001; 938: 36-45.
174. Petit I, Szyper-Kravitz M, Nagler A, Lahav M, Peled A, Habler L, et al. G-CSF induces stem cell mobilization by decreasing bone marrow SDF-1 and up-regulating CXCR4. Nat Immunol 2002; 3: 687-694
175. Li N, Lu X, Zhao X, Xiang FL, Xenocostas A, Karmazyn M, et al. Endothelial nitric oxide synthase promotes bone marrow stromal cell migration to the ischemic myocardium via upregulation of stromal cell-derived factor-1alpha. Stem Cells 2009; 27: 961-970
176. Kuang S, Rudnicki MA. The emerging biology of satellite cells and their therapeutic potential. Trends Mol Med 2008; 14: 82-91.
177. Massague J. The transforming growth factor-beta family. Annu Rev Cell Biol 1990; 6: 597-641.
178. Chang H, Brown CW, Matzuk MM. Genetic analysis of the mammalian transforming growth factor-beta superfamily. Endocr Rev 2002; 23: 787-823.
179. Dunker N, Krieglstein K. Targeted mutations of transforming growth factor-b genes reveal important roles in mouse development and adult homeostasis. Eur J Biochem 2000; 267: 6982-6988
180. Bujak M, Frangogiannis NG. The role of TGF-beta signaling in myocardial infarction and cardiac remodeling. Cardiovasc Res 2007; 74: 184-195
181. Bartram U, Molin DG, Wisse LJ, Mohamad A, Sanford LP, Doetschman T, et al. Double-outlet right ventricle and overriding tricuspid valve reflect disturbances of looping, myocardialization, endocardial cushion differentiation, and apoptosis in TGF-beta(2)- knockout mice. Circulation 2001; 103: 2745-2752
182. Liu AC, Gotlieb AI. Transforming growth factor-beta regulates in vitro heart valve repair by activated valve interstitial cells. Am J Pathol 2008; 173: 1275-1285
183. Lim H, Zhu YZ. Role of transforming growth factor-beta in the progression of heart failure. Cell Mol Life Sci 2006; 63: 2584-2596
184. Ikeuchi M, Tsutsui H, Shiomi T, Matsusaka H, Matsushima S, Wen J, et al. Inhibition of TGF-beta signaling exacerbates early cardiac dysfunction but prevents late remodeling after infarction. Cardiovasc Res 2004; 64: 526-535
185. Gwak SJ, Bhang SH, Yang HS, Kim SS, Lee DH, Lee SH, et al. In vitro cardiomyogenic differentiation of adipose-derived stromal cells using transforming growth factor-b1. Cell Biochem Funct 2009; 27: 148-154
186. Abdel-Latif A, Zuba-Surma EK, Case J, Tiwari S, Hunt G, Ranjan S, et al. TGF-beta1 enhances cardiomyogenic differentiation of skeletal muscle-derived adult primitive cells. Basic Res Cardiol 2008; 103: 514-524
187. Penn MS, Mangi AA. Genetic enhancement of stem cell engraftment, survival, and efficacy. Circ Res 2008; 102: 1471-1482
188. Schierling W, Kunz-Schughart LA, Muders F, Riegger GA, Griese DP. Fates of genetically engineered haematopoietic and mesenchymal stem cell grafts in normal and injured rat hearts. J Tissue Eng Regen Med 2008; 2: 354-364
189. Higuchi K, Medin JA. Lentiviral vectors for gene therapy of heart disease. J Cardiol 2007; 49: 1-11.
190. Gray SJ, Samulski RJ. Optimizing gene delivery vectors for the treatment of heart disease. Expert Opin Biol Ther 2008; 8: 911-922
191. Haider HK, Elmadbouh I, Jean-Baptiste M, Ashraf M. Nonviral vector gene modification of stem cells for myocardial repair. Mol Med 2008; 14: 79-86.
192. Smith LC, Eisensmith RC, Woo SL. Gene therapy in heart disease. Adv Exp Med Biol 1995; 369: 79-88.
193. Wattanapitayakul SK, Bauer JA. Recent developments in gene therapy for cardiac disease. Biomed Pharmacother 2000; 54: 487-504.
194. Symes JF. Gene therapy for ischemic heart disease: therapeutic potential. Am J Cardiovasc Drugs 2001; 1: 159-166
195. Askari AT, Penn MS. Targeted gene therapy for the treatment of cardiac dysfunction. Semin Thorac Cardiovasc Surg 2002; 14: 167-177
196. Melo LG, Pachori AS, Kong D, Gnecchi M, Wang K, Pratt RE, et al. Gene and cell-based therapies for heart disease. FASEB J 2004; 18: 648-663
197. Staudacher DL, Flugelman MY. Cell and gene therapies in cardiovascular disease with special focus on the no option patient. Curr Gene Ther 2006; 6: 609-623
198. Dunbar CE, Emmons RV. Gene transfer into hematopoietic progenitor and stem cells: progress and problems. Stem Cells 1994; 12: 563-576
199. Mangi AA, Noiseux N, Kong D, He H, Rezvani M, Ingwall JS, et al. Mesenchymal stem cells modified with Akt prevent remodeling and restore performance of infarcted hearts. Nat Med 2003; 9: 1195-1201
200. Askari A, Unzek S, Goldman CK, Ellis SG, Thomas JD, DiCorleto PE, et al. Cellular, but not direct, adenoviral delivery of vascular endothelial growth factor results in improved left ventricular function and neovascularization in dilated ischemic cardiomyopathy. J Am Coll Cardiol 2004; 43:1908-1914
201. Spiegelstein D, Kim C, Zhang Y, Li G, Weisel RD, Li RK, et al. Combined transmyocardial revascularization and cell-based angiogenic gene therapy increases transplanted cell survival. Am J Physiol Heart Circ Physiol 2007; 293: H3311-6.
202. Kim C, Li RK, Li G, Zhang Y, Weisel RD, Yau TM. Effects of cell-based angiogenic gene therapy at 6 months: persistent angiogenesis and absence of oncogenicity. Ann Thorac Surg 2007; 83: 640-646
203. Salva MZ, Himeda CL, Tai PW, Nishiuchi E, Gregorevic P, Allen JM, et al. Design of tissue-specific regulatory cassettes for highlevel rAAV-mediated expression in skeletal and cardiac muscle. Mol Ther 2007; 15: 320-329
204. Bian J, Popovic ZB, Benejam C, Kiedrowski M, Rodriguez LL, Penn MS. Effect of cell-based intercellular delivery of transcription factor GATA4 on ischemic cardiomyopathy. Circ Res 2007; 100: 1626-1633
205. Deasy BM, Huard J. Gene therapy and tissue engineering based on muscle-derived stem cells. Curr Opin Mol Ther 2002; 4: 382-389
206. Dowell JD, Rubart M, Pasumarthi KBS, Soonpaa MH, Field LJ. Myocyte and myogenic stem cell transplantation in the heart. Cardiovasc Res 2003; 58: 336-350
207. Joggerst SJ, Hatzopoulos AK. Stem cell therapy for cardiac repair: benefits and barriers. Expert Rev Mol Med 2009; 11: e20.
208. Koh GY, Kim SJ, Klug MG, Park K, Soonpaa MH, Field LJ. Targeted expression of transforming growth factor-beta 1 in intracardiac grafts promotes vascular endothelial cell DNA synthesis. J Clin Invest 1995; 95: 114-121
209. Aharinejad S, Abraham D, Paulus P, Zins K, Hofmann M, Michlits W, et al. Colony-stimulating factor-1 transfection of myoblasts improves the repair of failing myocardium following autologous myoblast transplantation. Cardiovasc Res 2008; 79: 395-404.
210. Rong SL, Lu YX, Liao YH, Wang XL, Wang YJ, Chang C, et al. Effects of transplanted myoblasts transfected with human growth hormone gene on improvement of ventricular function of rats. Chin Med J 2008; 121: 347-354
211. Gao Y, Lu Y, Mi S, Liu X, Su G, Rong S. Change of p16(INK4a) and PNCA protein expression in myocardium after injection of hIGF-1 gene modified skeletal myoblasts into post-infarction rats. J Huazhong Univ Sci Technol Med Sci 2008; 28: 396-400.
212. Roell W, Lewalter T, Sasse P, Tallini YN, Choi BR, Breitbach M, et al. Engraftment of connexin 43-expressing cells prevents postinfarct arrhythmia. Nature 2007; 450: 819-824
213. Haider HK, Ye L, Jiang S, Ge R, Law PK, Chua T, et al. Angiomyogenesis for cardiac repair using human myoblasts as carriers of human vascular endothelial growth factor. J Mol Med 2004; 82: 539-549
214. Ye L, Haider HK, Jiang S, Tan RS, Ge R, Law PK, et al. Improved angiogenic response in pig heart following ischaemic injury using human skeletal myoblast simultaneously expressing VEGF165 and angiopoietin-1. Eur J Heart Fail 2007; 9: 15-22.
215. Elmadbouh I, Haider HK, Jiang S, Idris NM, Lu G, Ashraf M. Ex vivo delivered stromal cell-derived factor-1alpha promotes stem cell homing and induces angiomyogenesis in the infarcted myocardium. J Mol Cell Cardiol 2007; 42: 792-803.
216. Yau TM, Kim C, Ng D, Li G, Zhang Y, Weisel RD, et al. Increasing transplanted cell survival with cell-based angiogenic gene therapy. Ann Thorac Surg 2005; 8: 1779-1786
217. Becker C, Lacchini S, Muotri AR, da Silva GJ, Castelli JB, Vassallo PF, et al. Skeletal muscle cells expressing VEGF induce capillary formation and reduce cardiac injury in rats. Int J Cardiol 2006; 113: 348-354
218. Deglurkar I, Mal N, Mills WR, Popovic ZB, McCarthy P, Blackstone EH, et al. Mechanical and electrical effects of cell-based gene therapy for ischemic cardiomyopathy are independent. Hum Gene Ther 2006; 17: 1144-1151
219. Nistri S, Bigazzi M, Bani D. Relaxin as a cardiovascular hormone. Physiology, pathophysiology and therapeutic promises. Cardiovasc Hematol Agents Med Chem (CHA-MC) 2007; 5: 101-108
220. Dschietzig T, Richter C, Bartsch C, Laule M, Armbruster FP, Baumann G, et al. The pregnancy hormone relaxin is a player in human heart failure. FASEB J 2001; 15: 2187-2195
221. Hsu SY, Nakabayashi K, Nishi S, Kumagai J, Kudo M, Sherwood OD, et al. Activation of orphan receptors by the hormone relaxin. Science 2002; 295: 671-674
222. Bani D, Bigazzi M. Clinical aspects and therapeutic perspectives of relaxin. Curr Med Chem-Immunol, Endocr Metab Agents 2005; 5: 403-410
223. Samuel CS, Du XJ, Bathgate RAD, Summers RJ. Relaxin' the stiffened heart and arteries: the therapeutic potential for relaxin in the treatment of cardiovascular disease. Pharm Ther 2006; 112: 529-552
224. Bani Sacchi T, Bigazzi M, Bani D, Mannaioni PF, Masini E. Relaxin-induced increased coronary flow through stimulation of nitric oxide production. Br J Pharmacol 1995; 116: 1589-1594
225. Bani D, Masini E, Bello MG, Bigazzi M, Bani Sacchi T. Relaxin protects against myocardial injury caused by ischemia and reperfusion in rat heart. Am J Pathol 1998; 152: 1367-1376
226. Samuel CS, Unemori EN, Mookerjee I, Bathgate RA, Layfield SL, Mak J, et al. Relaxin modulates cardiac fibroblast proliferation, differentiation and collagen production and reverses cardiac fibrosis in vivo. Endocrinology 2003; 145: 4125-4133
227. Perna AM, Masini E, Nistri S, Briganti V, Chiappini L, Stefano P, et al. Novel drug development opportunity for relaxin in acute myocardial infarction: evidences from a swine model. FASEB J 2005; 19: 1525-1527
228. Teerlink JR, Metra M, Felker GM, Panikowski P, Voors AA, Weatherley BD, et al. Relaxin for the treatment of patients with acute heart failure (Pre-RELAX-AHF): a multicentre, randomised, placebo-controlled, parallel-group, dose-finding phase IIb study. Lancet 2009; 373: 1429-1439
229. Formigli L, Zecchi-Orlandini S, Meacci E, Bani D. Skeletal Myoblasts for Heart Regeneration and Repair: State of the Art and Perspectives on the Mechanisms for Functional Cardiac Benefits. Curr Pharm Des 2009; 16(8): 915-928.
230. Papaioannou TG, Protogerou AD, Stamatelopoulos KS, Vavuranakis M, Stefanadis C. Non-invasive methods and techniques for central blood pressure estimation: procedures, validation, reproducibility and limitations. Curr Pharm Des 2009; 15(3): 245-253
231. Tamaki T, Uchiyama Y, Akatsuka A. Plasticity and Physiological Role of Stem Cells Derived from Skeletal Muscle Interstitium: Contribution to Muscle Fiber Hyperplasia and Therapeutic Use. Curr Pharm Des 2009; 16(8): 956-967.